A study published in Nature on September 2, 2026 reported that semaglutide, the GLP-1 peptide sold as Ozempic and Wegovy, extended median lifespan in aged mice by roughly 12 percent. The finding has generated significant attention in longevity research circles, but it is an animal study, not evidence that semaglutide extends human lifespan.
What the Study Found
Researchers at the University of California, Berkeley, led by Y. Feng and colleagues, treated 20-month-old female mice, roughly equivalent to late middle age for the animals, with semaglutide and compared them to untreated controls. The control group had a median lifespan of 742 days; treated mice reached a median of 834 days. The authors reported that treatment "improved physiological function, attenuated hallmarks of aging, and modulated nutrient sensors," alongside a roughly 24 percent reduction in food intake in the treated group.
How the Study Was Done
This was a controlled animal experiment: a defined treated group compared against an untreated control group of the same age, strain, and sex, with lifespan and physiological markers tracked over time. That design lets researchers draw more confident conclusions about the drug's effect within this mouse population than an uncontrolled observation would allow. It does not, on its own, establish how the drug behaves in a genetically diverse human population over a human lifespan.
What It Doesn't Show
Outside experts were quick to flag the limits of the result. Richard DiMarchi, a longevity researcher not involved in the study, noted that the results "align with expectations" for a GLP-1 drug but cautioned that "translation to humans is much more complex given the inbred nature of mice." Laboratory mice are bred to be genetically uniform, which makes them useful for isolating a drug's effect but a poor stand-in for the genetic and environmental diversity of human aging. The study also does not identify how much of the lifespan extension is simply downstream of reduced food intake and body weight, versus a more direct anti-aging mechanism, something the authors themselves say needs further study.
Why This Distinction Matters
This site has covered elsewhere why animal evidence and human clinical evidence are different categories of proof, not points on the same scale. Semaglutide already has an unusually strong human evidence base for its FDA-approved uses in type 2 diabetes and chronic weight management, including large outcome trials like SELECT that measured cardiovascular events in humans. Longevity, specifically extending healthy lifespan in humans who are not being treated for diabetes or obesity, is a separate, unapproved use with no human trial data behind it. No regulatory body has evaluated, let alone approved, semaglutide as a longevity therapy for otherwise healthy people.
The Bottom Line
The mouse data is a legitimate, peer-reviewed contribution to aging research, and it is consistent with a broader body of animal work suggesting metabolic drugs can influence lifespan in lab models. But it is a starting point for further research, not a basis for using semaglutide off-label for anti-aging purposes. Anyone curious about GLP-1 drugs and healthy aging should discuss the actual, FDA-approved evidence with a licensed physician rather than extrapolating from a mouse study to their own life expectancy.